Starton Therapeutics Receives Authorization from the FDA to

FDA agrees to the planned Phase 1b study in second-line transplant-ineligible patients in multiple myelomaTreatment regimen will include Velcade® (bortezomib) and dexamethasone and replace oral Revlimid® with STAR-LLDPARAMUS, N.J.--(BUSINESS WIRE)--Starton Therapeutics Inc. (“Starton” or “the Company”), a clinical s...

Related Keywords

Delaware , United States , Pedro Lichtinger , Healthwell Pubco , Jamie Oliver , Healthwell Acquisition Corp , Nasdaq , Starton Therapeutics Inc , Drug Administration , Exchange Commission , Holdings Corp , Starton Therapeutics , Healthwell Acquisition , About Starton , Combination Agreement , Registration Statement , Business Combination Agreement , Merger Agreement , Annual Report , While Starton , Securities Act ,